LINKS: ....Medical Dictionary....Stress Management....Brain Food....Your Memory Enhancer....Brain Facts....Neurotech....Success Tips....Free....World Travel Guide....Boston Tour Guide....Makeup.Fashion....Allergy Info....Bird Flu Alarm
2005-12-06-Ranbaxy Launches Two New Anti-Hiv Products In India On World Aids Day
Ranbaxy Laboratories Limited (RLL) announced today that the Company is introducing two new anti-HIV products, Virolis-E and Virocomb-E, in India. Both products contain three Anti Retroviral drugs each and offer WHO recommended first line Highly Active Anti Retroviral Therapy (HAART) in convenient daily use packs.
Commenting on the development, Dr. Brian Tempest, CEO and MD, RLL said, “We are pleased to introduce the innovative products, Virolis-E and Virocomb-E, that aim to make HIV treatment easier to administer and use. Ranbaxy is committed to HIV care and this is yet another step in our endeavour to make high quality, affordable and patient friendly ARVs available worldwide.”
The products are designed to improve compliance with HAART which is presently a challenge faced by both patients and healthcare providers. In most countries outside India, these products will be labeled and sold under the Coviro-E and Avocomb-E brand names respectively.
Virolis-E is a first of its kind product in the world. It is a compliance pack containing two fixed dose combination tablets of Lamivudine 150mg & Stavudine 30/40mg and one tablet of Efavirenz 600mg.
Virocomb-E is also a compliance pack and contains two fixed dose combination tablets of Lamivudine 150mg & Zidovudine 300mg and one tablet of Efavirenz 600mg.
Virolis-E and Virocomb-E are indicated for treatment of HIV-1 infection. These products will make available Efavirenz based HAART regimens in convenient daily packs in addition to the convenient Nevirapine based regimens already made available by Ranbaxy.
The products are coded with easy to decipher graphics to indicate the time when drugs need to be consumed. The WHO also encourages such presentation, as they are expected to enhance compliance to anti-HIV therapy.
Ranbaxy's ARV's are manufactured at the Company's state-of-the-art manufacturing facilities that have been inspected and approved by some of the most stringent agencies in the world, including USFDA and WHO. The Contract Research Organisations (CROs) used by Ranbaxy to carry out bio-equivalence studies for its ARV's are globally reputed and conduct and file their studies routinely with some of the most stringent regulatory authorities around the world.
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries.